LATS1
ENSG00000131023
Target class
Kinase
Chromosome
6
- Chemical probe available
- No
- Other names
- WARTS
- Target name
- LATS1
- Gene name
- Large tumor suppressor kinase 1
- Gene symbol
- LATS1
- Protein name
- Serine/threonine-protein kinase LATS1 (EC 2.7.11.1) (Large tumor suppressor homolog 1) (WARTS protein kinase) (h-warts)
- Gene biotype
- Protein coding
- Gene family
- Large tumor suppressor kinase family
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 18.94
- Tissue specificity (Gini)
- 0.281
- Tissue specificity (tau)
- 0.49
- KEGG gene identifiers
- hsa:9113
- Reactome pathways
- R-HSA-2028269
- Protein interaction confidence
- 0.8965
- Protein interaction partners
- 32
- End position
- 149718105
- Start position
- 149658153
- Chromosome
- 6
- Strand
- Reverse
- Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, spindle . Midbody . Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body . Note=Localizes to the centrosomes throughout interphase but migrates to the mitotic apparatus, including spindle pole bodies, mitotic spindle, and midbody, during mitosis. .
Publication evidence
- PubMed 10518011
- Tissue specificity (tau)
- 0.490486
- Expression inequality (Gini)
- 0.281252
Expression in transcripts per million
- Ovary
- 18.94
- Uterus
- 18.57
- Cervix - Ectocervix
- 18.33
- Cervix - Endocervix
- 17.95
- Brain - Cerebellar Hemisphere
- 17.18
Expression in transcripts per million
- Ovary18.94
- Uterus18.57
- Cervix - Ectocervix18.33
- Cervix - Endocervix17.95
- Brain - Cerebellar Hemisphere17.18
- Nerve - Tibial16.12
- Brain - Cerebellum15.86
- Fallopian Tube15.41
- Artery - Tibial14.68
- Cells - Cultured fibroblasts14.23
- Vagina14.17
- Bladder13.9
- Cells - EBV-transformed lymphocytes13.47
- Artery - Coronary13.23
- Adipose - Subcutaneous13.07
- Artery - Aorta13
- Colon - Sigmoid13
- Breast - Mammary Tissue12.87
- Prostate12.76
- Thyroid12.49
- Lung12.13
- Esophagus - Gastroesophageal Junction11.88
- Esophagus - Muscularis11.77
- Testis11.11
- Skin - Sun Exposed (Lower leg)10.78
And 29 more, listed on the interactive page.
- GO:0000086
- GO:0000819
- GO:0006468
- GO:0030833
- GO:0033146
- GO:0035329
- GO:0043254
- GO:0045736
- GO:0060644
- GO:0090090
- GO:1900181
- GO:1900227
- GO:2000058
- GO:0000922
- GO:0005737
- GO:0005815
- GO:0005829
- GO:0030496
- GO:0000287
- GO:0004674
- GO:0005515
- GO:0005524
- GO:0019901
- GO:0030331
- GO:0106310
Related records
Trials (576)
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
- A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
- A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
- A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
- A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours
- A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
- A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
- A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
- A Phase 1b Trial in Patients With Renal Cell Cancer
- A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
- A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
- A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
- A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
Drugs (7)
- AST-487
- Defactinib
- Lestaurtinib
- Midostaurin
- Nintedanib
- PF-03758309
- Sunitinib